236 related articles for article (PubMed ID: 30323610)
1. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.
Skroza N; Bernardini N; Proietti I; Potenza C
Ther Clin Risk Manag; 2018; 14():1879-1885. PubMed ID: 30323610
[TBL] [Abstract][Full Text] [Related]
2. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Ingenol Mebutate in the Treatment of Actinic Keratoses: A Pre- and Posttreatment Dermoscopic Comparative Analysis.
Carbotti M; Coppola R; Zanframundo S; Devirgiliis V; Panasiti V
Biomed Res Int; 2018; 2018():4381019. PubMed ID: 30246021
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and tolerability of field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a single center case series.
Bobyr I; Campanati A; Consales V; Giuliodori K; Scalise A; Offidani A
Springerplus; 2016; 5():627. PubMed ID: 27330893
[TBL] [Abstract][Full Text] [Related]
6. Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study.
Ricci F; Tambone S; Neri L; Fania L; Piccioni A; Guerriero C; Fargnoli MC; Peris K
J Dermatolog Treat; 2016 Nov; 27(6):525-530. PubMed ID: 27043050
[TBL] [Abstract][Full Text] [Related]
7. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
Stockfleth E; Bastian M
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
[TBL] [Abstract][Full Text] [Related]
9. Identification of differentially expressed genes in actinic keratosis samples treated with ingenol mebutate gel.
Segura S; Gadea A; Nonell L; Andrades E; Sánchez S; Pujol R; Hernández-Muñoz I; Toll A
PLoS One; 2020; 15(5):e0232146. PubMed ID: 32413042
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate treatment in actinic keratosis - clinical effectiveness and potential side effects.
Lesiak A; Maćkowska A; Bednarski IA; Kolano P; Olejniczak-Staruch I; Woźniacka A; Sieniawska J; Narbutt J
Postepy Dermatol Alergol; 2019 Aug; 36(4):468-471. PubMed ID: 31616223
[TBL] [Abstract][Full Text] [Related]
12. Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis.
Goldenberg G; Berman B
Clin Cosmet Investig Dermatol; 2015; 8():1-8. PubMed ID: 25565875
[TBL] [Abstract][Full Text] [Related]
13. Ingenol mebutate: A novel topical drug for actinic keratosis.
Aditya S; Gupta S
Indian Dermatol Online J; 2013 Jul; 4(3):246-9. PubMed ID: 23984250
[TBL] [Abstract][Full Text] [Related]
14. Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study.
Emilio J; Schwartz M; Feldman E; Bieber AK; Bienenfeld A; Jung MK; Siegel DM; Markowitz O
Clin Cosmet Investig Dermatol; 2016; 9():89-93. PubMed ID: 27143946
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
16. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L
Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871
[TBL] [Abstract][Full Text] [Related]
18. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
Berman B; Nestor MS; Newburger J; Park H; Swenson N
J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
[TBL] [Abstract][Full Text] [Related]
19. Ingenol Mebutate Is Associated With Increased Reporting Odds for Squamous Cell Carcinoma in Actinic Keratosis Patients, a Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Jedlowski PM
J Cutan Med Surg; 2023; 27(1):39-43. PubMed ID: 36495205
[TBL] [Abstract][Full Text] [Related]
20. Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases.
Longo C; Borsari S; Benati E; Moscarella E; Alfano R; Argenziano G
Dermatol Ther (Heidelb); 2016 Mar; 6(1):81-7. PubMed ID: 26847171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]